Esta página se tradujo automáticamente y no se garantiza la precisión de la traducción. por favor refiérase a versión inglesa para un texto fuente.

Multiparametric Metabolic and Hypoxic PET/MRI Imaging Substudy in Gliomas

20 de agosto de 2026 actualizado por: Anna G. Sorace, University of Alabama at Birmingham

Multiparametric Metabolic and Hypoxic PET/MRI Imaging Substudy for Disease Assessment and Guidance of Catheters in Patients With Recurrent/Progressive Malignant Gliomas Eligible for Catheter-delivered Therapies

This substudy will investigate a new imaging approach using positron emission tomography (PET) and two investigational drugs ([18F]FET and [18F]FMISO) to see if the imaging results will help with the placement of catheters for therapy delivery in 20 adult patients with malignant gliomas (MGs) who are participating in the UAB IRB approved main study, A Phase I/II Study of Pembrolizumab and M032 (NSC 733972), a Genetically Engineered HSV-1 Expressing IL-12, in Patients with Recurrent/Progressive and Newly Diagnosed Glioblastoma Multiforme, grade 3 or grade 4 astrocytoma, or Gliosarcoma (IRB 300007756 PI Markert). The PET and MR imaging results will be available to guide catheter placement within IRB 300007756 study-specific guidelines during Neurosurgery.

Descripción general del estudio

Estado

Aún no reclutando

Condiciones

Intervención / Tratamiento

Descripción detallada

Pre-Study Consent Visit

This visit will take 0.5 hours and may take place during your neuro-oncology clinic visit or in the Division of Molecular Imaging and Therapeutics in Jefferson Tower or the Wallace Tumor Institute. Participants will be asked to sign this consent form before any study procedures. Participants will have a blood test to measure their kidney function. If participants have already had lab tests to determine kidney function within 4 weeks, they do not have to be repeated. Women of childbearing potential will have a urine pregnancy test or have had a blood test within 48 hours of consenting. If the participant is eligible, they will be scheduled to return for baseline imaging within 21 days before surgery.

Once consented, participants will fill out an MRI screening questionnaire in person or through a screening phone call. These questions will help identify and address items like claustrophobia. If participants are anxious or claustrophobic (anxious due to being in a confined area) due to the PET/MRI imaging procedures, a study physician will call in lorazepam (Ativan), 0.5 mg-1 mg based on individual patient assessment, to a pharmacy of the participants choice. One tablet is to be taken with each imaging visit as necessary. Participants will be responsible for paying for the medication and the study will not reimburse them. Participants will need to pick up the medication and bring it with them to each study visit. This medication may make participants drowsy, and they should not drive for 12 hours after taking this medication. Participants must make arrangements to have a responsible adult present to provide them with transportation home after each visit. Participants should also avoid drinking alcohol or taking opioid pain medications for at least 12 hours or use dangerous equipment after taking this medication. Additional FDA information will be given to participants during this visit describing this medication and known side effects.

Baseline Imaging (performed within 21 days of surgery)

Participants will be scheduled to have baseline imaging performed during one or two separate days based on their preference and scanner and drug production availability.

  1. DAY - Baseline Combo FMISO/FET-PET/MRI Imaging Visit

    If participants are scheduled for baseline imaging performed during one (1) day, this visit will take about 6.5 hours. Participants will be asked to not eat or drink anything with calories for 4 hours prior to the study. When participants arrive at the Advanced Imaging Facility (AIF), located in the Wallace Tumor Institute (WTI), they will have another chance to have any questions answered about the procedure.

    If participants have been prescribed lorazepam to help reduce anxiety, the study coordinator will verify they have a driver and/or transportation present. Participants will take 1 tablet by mouth upon arrival or at least one hour before the imaging procedure.

    Female participants of childbearing potential will have either a blood draw or urine pregnancy test within 48 hours before administration of the radioactive drug to make sure they are not pregnant.

    Before the scan, participants will have a plastic catheter inserted into a vein in each arm. Participants will be injected with [18F]FMISO and they will wait 4 hours for the drug to distribute in the body. Participants will then be positioned in the PET/MRI scanner and scanned for up to 30 minutes during which time they will receive an injection of gadolinium MR contrast agent.

    Immediately following the FMISO-PET/MRI imaging, participants will receive an injection of [18F]FET and will be imaged for another 40 minutes.

    Participants will be monitored during the imaging to make sure they are not experiencing any side effects and those taking lorazepam will be monitored for confusion or disorientation.

    When participants have completed the PET/MRI imaging, the catheters will be removed, and they may resume normal activities.

    Participants will receive a follow-up phone call within 48 hours of their imaging visit. Participants will be asked about any changes in their health and side effects that might be due to the investigational drug.

  2. DAY - Baseline Separate FMISO-PET/MRI and FET-PET/MRI Imaging Visits

If participants are scheduled for baseline imaging to be performed over two (2) separate days, every effort will be made to schedule these two visits within 1 week (7 days) of each other. One visit will take 2 hours and the other will take 5 hours. FET-PET/MRI will typically be performed first although the order can be switched if needed due to drug production or scanner availability.

FET-PET/MRI imaging - baseline visit (2-Day)

This visit will take about 2 hours. Participants will be asked to not eat or drink anything with calories for 4 hours prior to the study. When participants arrive at the Advanced Imaging Facility (AIF), located in the Wallace Tumor Institute (WTI), they will have another chance to have any questions answered about the procedure.

If participants have been prescribed lorazepam to help reduce anxiety, the study coordinator will verify they have a driver and/or transportation present. participants will take 1 tablet by mouth upon arrival or at least one hour before the imaging procedure.

Female participants of childbearing potential will have either a blood draw or urine pregnancy test within 48 hours before administration of the radioactive drug to make sure they are not pregnant.

Before the scan, participants will have a plastic catheter inserted into a vein in one or both arm(s) and positioned in the PET/MRI. Participants will be injected with [18F]FET and imaged for up to 40 minutes during which time they will receive an injection of gadolinium MR contrast agent.

Participants will be monitored during the imaging to make sure they are not experiencing any side effects and those taking lorazepam will be monitored for confusion or disorientation.

When participants have completed the PET/MRI imaging, the catheters will be removed, and they may resume normal activities.

Participants will receive a follow-up phone call within 48 hours of their imaging visit. Participants will be asked about any changes in their health and side effects that might be due to the investigational drug.

FMISO-PET/MRI imaging - baseline visit (2-Day)

This visit will take up to 5 hours. No fasting or other special preparation is required for this visit. When participants arrive at the Advanced Imaging Facility (AIF), located in the Wallace Tumor Institute (WTI), they will have another chance to have any questions answered about the procedure.

If participants have been prescribed lorazepam to help reduce anxiety, the study coordinator will verify they have a driver and/or transportation present. participants will take 1 tablet by mouth upon arrival or at least one hour before the imaging procedure.

Female participants of childbearing potential will have either a blood draw or urine pregnancy test within 48 hours before administration of the radioactive drug to make sure they are not pregnant.

Before the scan, participants will have a plastic catheter inserted into a vein in one or both arms. Participants will be injected with [18F]FMISO and they will wait 4 hours for the drug to distribute in the body. Participants will then be positioned in the PET/MRI scanner and scanned for up to 30 minutes during which time they will receive an injection of gadolinium MR contrast agent.

Participants will be monitored during the imaging to make sure they are not experiencing any side effects and those taking lorazepam will be monitored for confusion or disorientation.

When participants have completed the PET/MRI imaging, the catheters will be removed, and they may resume normal activities.

Participants will receive a follow-up phone call within 48 hours of their imaging visit. Participants will be asked about any changes in their health and side effects that might be due to the investigational drug.

Post Surgery Follow up FET-PET/MRI visits

After the participant's surgery as directed under the main study (IRB 300007756), they will be scheduled for follow-up FET-PET/MRI imaging at approximately 1 month, 3 months and 6-8 months.

Each of these visits will take about 2 hours. Participants will be asked to not eat or drink anything with calories for 4 hours prior to each imaging visit.

If participants have been prescribed lorazepam to help reduce anxiety, the study coordinator will verify they have a driver and/or transportation present. participants will take 1 tablet by mouth upon arrival or at least one hour before the imaging procedure.

Female participants of childbearing potential will have either a blood draw or urine pregnancy test within 48 hours before administration of the radioactive drug to make sure they are not pregnant.

Before the scan, participants will have a plastic catheter inserted into a vein in one or both arm(s) and positioned in the PET/MRI. Participants will be injected with [18F]FET and imaged for up to 40 minutes during which time they will receive an injection of gadolinium MR contrast agent.

Participants will be monitored during the imaging to make sure they are not experiencing any side effects and those taking lorazepam will be monitored for confusion or disorientation.

When participants have completed the PET/MRI imaging, the catheters will be removed, and they may resume normal activities.

Participants will receive a follow-up phone call within 48 hours of their imaging visit. Participants will be asked about any changes in their health and side effects that might be due to the investigational drug.

If the PET/MRI is unexpectedly unavailable during any of the imaging visits, participants may undergo brain PET imaging on a scanner located in an adjacent room to the PET/MRI. The radioactive drug administration and PET imaging will be identical to the protocol described above for PET/MRI but participants will not receive MRI contrast.

Clinical follow up

The study team will continue to follow participant's health through their regular clinic visits and imaging as directed under the main study (IRB 300007756).

Tipo de estudio

Intervencionista

Inscripción (Estimado)

20

Fase

  • Fase temprana 1

Contactos y Ubicaciones

Esta sección proporciona los datos de contacto de quienes realizan el estudio e información sobre dónde se lleva a cabo este estudio.

Estudio Contacto

  • Nombre: Sebastian Eady
  • Número de teléfono: 205-996-2636
  • Correo electrónico: smeady@uabmc.edu

Ubicaciones de estudio

    • Alabama
      • Birmingham, Alabama, Estados Unidos, 35249
        • UAB

Criterios de participación

Los investigadores buscan personas que se ajusten a una determinada descripción, denominada criterio de elegibilidad. Algunos ejemplos de estos criterios son el estado de salud general de una persona o tratamientos previos.

Criterio de elegibilidad

Edades elegibles para estudiar

  • Adulto
  • Adulto Mayor

Acepta Voluntarios Saludables

No

Descripción

Inclusion Criteria:

  1. Participants from IRB 300007756
  2. 18 years of age or older at the time of enrollment
  3. Able to undergo PET/MRI without anesthesia or sedation. Minimal sedation with ananxiolytic such as alprazolam used routinely for SOC MRI is allowed.
  4. Females with childbearing potential must have a negative urine β-hCG test on the day of procedure or a serum hCG test within 48 hours prior to the administration of FET or FMISO.
  5. ECOG performance score of 2 or better
  6. Life expectancy greater than 12 weeks.

Exclusion Criteria:

  1. Any exclusions listed in IRB 300007756
  2. Pregnancy or breast feeding
  3. Inability to complete PET/MRI scans.
  4. Significant renal dysfunction (estimated GFR < 30 mL/min)
  5. Any condition which may interfere with ability to participate in or complete all study-related activities as assessed by the study team
  6. Unable to undergo MRI
  7. Contraindication to gadolinium-based contrast

Plan de estudios

Esta sección proporciona detalles del plan de estudio, incluido cómo está diseñado el estudio y qué mide el estudio.

¿Cómo está diseñado el estudio?

Detalles de diseño

  • Propósito principal: Diagnóstico
  • Asignación: N / A
  • Modelo Intervencionista: Asignación de un solo grupo
  • Enmascaramiento: Ninguno (etiqueta abierta)

Armas e Intervenciones

Grupo de participantes/brazo
Intervención / Tratamiento
Experimental: Glioma patients enrolled in main study [18F]FMISO and [18F]FET PET/MRI
FET and FMISO PET/MRI studies will be performed on either 1) same day or 2) separate days within 14 days of each other. Baseline imaging will occur within 21 days before surgery. Every effort will be made to perform these studies within 1 week of each other. FMISO-PET/MRI will be administered first with a four-hour uptake time followed by a dynamic FET-PET/MRI (<90 min total scan time). For separate scans, FET-PET/MRI will typically be performed first although the order can be switched if needed due to PET tracer production or scanner scheduling. Patients will fast for at least 4 hours prior to FET administration and will undergo dynamic scans. No fasting or other special preparation is required for FMISO studies and imaging will be acquired after a four-hour uptake time. Additional post-surgical FET-PET/MRI scans at 1, 3 and 6 months post will follow the same steps as the separately acquired scans except no additional FMISO-PET/MRI will be performed.
Glioma patients enrolled in the main study (IRB 300007756) will complete 4 to 5 imaging visits. Visit 1 will take place prior to participants scheduled surgery. Visit 1 could be two seperate imaging visits between [18F]FMISO and [18F]FET, if needed. Participants will have three additional [18F]FET PET/MRIs at 1 month, 3 months and 6 months post-surgery.

¿Qué mide el estudio?

Medidas de resultado primarias

Medida de resultado
Medida Descripción
Periodo de tiempo
The frequency of changes in catheter placement based on standard pre-surgical study-specific MRI versus standard MRI combined with results from FET/FMISO PET/MRI
Periodo de tiempo: Up to 24 weeks
Incidence and frequency that catheter placement changes following the addition of FET/FMISO PET/MRI.
Up to 24 weeks
The percent change in imaging metrics associated with FET-PET/MRI (PET (SUV) and MRI metrics (ADC, Ktrans)) from subsequent imaging visits to the baseline.
Periodo de tiempo: Up to 24 weeks
The incidence and percent change of PET (SUV) and MRI metrics (ADC, Ktrans) from subsequent imaging visits to the baseline.
Up to 24 weeks

Medidas de resultado secundarias

Medida de resultado
Medida Descripción
Periodo de tiempo
The variance of mathematical modeling predicted tumor volume to imaging-derived tumor volume (Standard-of-care; FET PET/MRI).
Periodo de tiempo: Up to 24 weeks
The incidence and variance of predicted tumor volume and imaging-derived tumor volume.
Up to 24 weeks

Colaboradores e Investigadores

Aquí es donde encontrará personas y organizaciones involucradas en este estudio.

Patrocinador

Investigadores

  • Investigador principal: Anna Sorace, PhD, University of Alabama at Birmingham

Fechas de registro del estudio

Estas fechas rastrean el progreso del registro del estudio y los envíos de resultados resumidos a ClinicalTrials.gov. Los registros del estudio y los resultados informados son revisados ​​por la Biblioteca Nacional de Medicina (NLM) para asegurarse de que cumplan con los estándares de control de calidad específicos antes de publicarlos en el sitio web público.

Fechas importantes del estudio

Inicio del estudio (Estimado)

1 de septiembre de 2026

Finalización primaria (Estimado)

1 de noviembre de 2030

Finalización del estudio (Estimado)

1 de noviembre de 2030

Fechas de registro del estudio

Enviado por primera vez

18 de agosto de 2026

Primero enviado que cumplió con los criterios de control de calidad

18 de agosto de 2026

Publicado por primera vez (Actual)

21 de agosto de 2026

Actualizaciones de registros de estudio

Última actualización publicada (Actual)

24 de agosto de 2026

Última actualización enviada que cumplió con los criterios de control de calidad

20 de agosto de 2026

Última verificación

1 de agosto de 2026

Más información

Términos relacionados con este estudio

Otros números de identificación del estudio

  • IRB-300017146

Plan de datos de participantes individuales (IPD)

¿Planea compartir datos de participantes individuales (IPD)?

NO

Información sobre medicamentos y dispositivos, documentos del estudio

Estudia un producto farmacéutico regulado por la FDA de EE. UU.

Sí

Estudia un producto de dispositivo regulado por la FDA de EE. UU.

No

Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .